Approval · Notice of Compliance 164 · 2004
IMITREX: Notice of Compliance 164
Issued March 2, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 164
- Date
- March 2, 2004
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Incorporate relevant clinical trial information into the product monograph
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMITREX | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 6 MG per 0.5ML
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB
- SUMATRIPTAN HEMISULFATE 5 MG per 0.1ML
- SUMATRIPTAN HEMISULFATE 20 MG per 0.1ML